According to TipRanks, Mayo is a 4-star analyst with an average return of 3.9% and a 48.76% success rate. Mayo covers the Healthcare sector, focusing on stocks such as Elevance Health, UnitedHealth, and Airsculpt Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $448.41 average price target, which is a 5.24% upside from current levels. In a report released on July 17, Barclays also maintained a Buy rating on the stock with a $429.00 price target.
Based on UnitedHealth’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $112.03 billion and a net profit of $5.48 billion. In comparison, last year the company earned a revenue of $111.62 billion and had a net profit of $3.41 billion
Based on the recent corporate insider activity of 123 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UNH in relation to earlier this year. Most recently, in April 2026, Patrick Hugh Conway, the CEO, Optum of UNH sold 800.00 shares for a total of $284,000.00.
